Publications by authors named "G Malara"
Guidelines How to Integrate Surgery and Targeted Therapy with Biologics for the Treatment of Hidradenitis Suppurativa: Delphi Consensus Statements from an Italian Expert Panel.
Dermatology
December 2024
Article Synopsis
- * Treatment methods for HS include a mix of medical therapies (like antibiotics and biologics) and surgical options, though many patients still experience high rates of recurrence and progression despite these treatments.
- * A recent meeting of Italian HS experts focused on improving treatment strategies, emphasizing the importance of integrating biologic therapy with surgical options, and identifying ten key areas that need further exploration to optimize patient care.
Article Synopsis
- * A study involving 118 adults with moderate-to-severe AD found that over half experienced sleep issues, severe itching, and frequent flare-ups, affecting their daily functioning.
- * Many patients reported significant disease impact on their lives, with around 37.3% indicating severe effects from AD, while one in four felt their current treatment was insufficient.
Gender differences in adult atopic dermatitis and clinical implication: Results from a nationwide multicentre study.
J Eur Acad Dermatol Venereol
February 2024
Background: Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults. However, limited research has been conducted on gender differences in AD.
Objectives: This study aimed to assess gender differences in adult AD patients, focusing on demographic and clinical features, comorbidities and treatment approaches.
Dimethyl fumarate (DMF) was recently approved by the European Medicines Agency for systemic treatment of moderateto- severe chronic plaque psoriasis. Appropriate management of DMF treatment is required to achieve optimal clinical benefits. 7 dermatology experts gathered online for 3 meetings to identify consensus on the use of DMF in patient selection, drug dosage/titration, side effects management, and follow-up, with the aim to provide guidance on the use of DMF for psoriasis in clinical dermatological practice based on literature data and expert opinion.
View Article and Find Full Text PDFPsoriasis is a chronic inflammatory disease which affects 29.5 million people worldwide and it can negatively impact quality of life, especially when it affects a special localization, such as nails, face, palms and soles, or intertriginous regions. Risankizumab is a humanized monoclonal antibody which targets the p19 subunit of interleukin-23 and it is currently licensed also as systemic therapy for moderate to severe plaque psoriasis.
View Article and Find Full Text PDF